ProPhase Labs Inc. recently addressed a regulatory issue concerning its compliance with Nasdaq Listing Rule 5605(c)(2)$(A)$, which mandates audit committee requirements. The issue arose following the resignation of Eleanor McBrier from the Board of Directors, creating a vacancy on the audit committee. On September 26, 2024, Nasdaq informed the company of its non-compliance and provided a cure period to rectify the situation. ProPhase Labs has since appointed Carolina Abenante as an independent director to fill the vacancy. With this appointment, Nasdaq confirmed on June 25, 2025, that ProPhase Labs is now in compliance with the listing requirements, effectively closing the matter.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.